**The primary driver of trader sentiment on marijuana rescheduling markets is the status of the DEA's expedited administrative hearing process for moving botanical cannabis from Schedule I to Schedule III.** In April 2026, the Department of Justice issued a final order immediately placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, providing those segments with DEA registration pathways and prospective relief from Section 280E tax restrictions while leaving adult-use and unlicensed bulk marijuana in Schedule I. An expedited hearing on broader rescheduling, directed by executive order, ran from June 29 to July 15, 2026; post-hearing transcripts and closing briefs released in late August and early September show the DEA arguing that cannabis meets Schedule III criteria based on HHS scientific review of accepted medical use and lower abuse potential. The administrative law judge's recommendation remains pending amid separate D.C. Circuit litigation, creating ongoing uncertainty over timelines for any final rule covering the wider market.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於$802,588 交易量
2026-12-31
9月30日
2%
12月31日
26%
$802,588 交易量
9月30日
$262 交易量
2%
12月31日
$192,755 交易量
26%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The primary driver of trader sentiment on marijuana rescheduling markets is the status of the DEA's expedited administrative hearing process for moving botanical cannabis from Schedule I to Schedule III.** In April 2026, the Department of Justice issued a final order immediately placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, providing those segments with DEA registration pathways and prospective relief from Section 280E tax restrictions while leaving adult-use and unlicensed bulk marijuana in Schedule I. An expedited hearing on broader rescheduling, directed by executive order, ran from June 29 to July 15, 2026; post-hearing transcripts and closing briefs released in late August and early September show the DEA arguing that cannabis meets Schedule III criteria based on HHS scientific review of accepted medical use and lower abuse potential. The administrative law judge's recommendation remains pending amid separate D.C. Circuit litigation, creating ongoing uncertainty over timelines for any final rule covering the wider market.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
市場開放時間： Feb 7, 2026, 5:04 PM ET
交易量
$802,588結束日期
2027-01-01市場開放時間
Feb 7, 2026, 5:04 PM ETThis market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The primary driver of trader sentiment on marijuana rescheduling markets is the status of the DEA's expedited administrative hearing process for moving botanical cannabis from Schedule I to Schedule III.** In April 2026, the Department of Justice issued a final order immediately placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, providing those segments with DEA registration pathways and prospective relief from Section 280E tax restrictions while leaving adult-use and unlicensed bulk marijuana in Schedule I. An expedited hearing on broader rescheduling, directed by executive order, ran from June 29 to July 15, 2026; post-hearing transcripts and closing briefs released in late August and early September show the DEA arguing that cannabis meets Schedule III criteria based on HHS scientific review of accepted medical use and lower abuse potential. The administrative law judge's recommendation remains pending amid separate D.C. Circuit litigation, creating ongoing uncertainty over timelines for any final rule covering the wider market.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
交易量
$802,588結束日期
2027-01-01市場開放時間
Feb 7, 2026, 5:04 PM ET**The primary driver of trader sentiment on marijuana rescheduling markets is the status of the DEA's expedited administrative hearing process for moving botanical cannabis from Schedule I to Schedule III.** In April 2026, the Department of Justice issued a final order immediately placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, providing those segments with DEA registration pathways and prospective relief from Section 280E tax restrictions while leaving adult-use and unlicensed bulk marijuana in Schedule I. An expedited hearing on broader rescheduling, directed by executive order, ran from June 29 to July 15, 2026; post-hearing transcripts and closing briefs released in late August and early September show the DEA arguing that cannabis meets Schedule III criteria based on HHS scientific review of accepted medical use and lower abuse potential. The administrative law judge's recommendation remains pending amid separate D.C. Circuit litigation, creating ongoing uncertainty over timelines for any final rule covering the wider market.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions